Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.0251 | 0.2736 | 0.6978 |
Trypanosoma brucei | developmentally regulated phosphoprotein | 0.0251 | 0.2736 | 0.6606 |
Leishmania major | mitochondrial DNA polymerase beta | 0.0335 | 0.3921 | 1 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.0335 | 0.3921 | 1 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0159 | 0.1428 | 0.3643 |
Brugia malayi | kinase, mitochondrial precursor | 0.0251 | 0.2736 | 1 |
Leishmania major | developmentally regulated phosphoprotein-like protein | 0.0251 | 0.2736 | 0.6606 |
Mycobacterium ulcerans | hypothetical protein | 0.0177 | 0.1681 | 0.5 |
Leishmania major | mitochondrial DNA polymerase beta-PAK, putative | 0.0159 | 0.1428 | 0.2862 |
Trypanosoma brucei | mitochondrial DNA polymerase beta | 0.0335 | 0.3921 | 1 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0766 | 1 | 1 |
Trypanosoma cruzi | pyruvate dehydrogenase (lipoamide) kinase, putative | 0.0088 | 0.0429 | 0.1094 |
Loa Loa (eye worm) | hypothetical protein | 0.0251 | 0.2736 | 1 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.0335 | 0.3921 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0177 | 0.1681 | 0.5 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0766 | 1 | 1 |
Trypanosoma brucei | mitochondrial DNA polymerase beta-PAK | 0.0159 | 0.1428 | 0.2862 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.0251 | 0.2736 | 0.0264 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0102 | 0.0626 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4.716 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.61 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.609 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.566 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.421 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.398 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.349 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.326 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.316 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.237 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.113 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.